Intravenous Cardioversion of Atrial Fibrillation (AF) Wit... | NCT00915356

NCT00915356

ID	Type	Description	Link
2009-009862-15 (EudraCT No)

Status Module

Sponsor/Collaborators Module

Oversight Module

Description Module

Conditions Module

Design Module

Interventional Study Design

Biospecimen

No data available

No data is available for this block.

Arms/Interventions Module

Label	Type	Description	Intervention Names
1	Experimental	AZD1305 iv infusion	Drug: AZD1305
2	Placebo Comparator	Placebo iv infusion	Drug: Placebo

Interventions

Name	Type	Description	Arm Group Labels	Other Names
AZD1305	Drug	Intravenous (iv) single infusion given intravenously until successful conversion of Atrial Fibrillation (AF) to Sinus Rhythm (SR) occur or for a maximum of 30 minutes

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Dose-response Relationship for QTcF Interval of AZD1305	QTcF-QT interval corrected for the RR interval (the time elapsing between two consecutive R waves in the electrocardiogram (ECG)) using the Fridericia formula.For each of 3 consecutive beats (5 consecutive beats if AF) a manual measurement, preferably in lead V2, of QTend intervals was done.The mean QT values of the 3 consecutive beats (5 consecutive beats if AF) were, together with RR intervals, date & time of the ECG, entered into the eCase Report Form (eCRF).The selected beats had to be marked with calipers and noted together with measured values and calculations on the print-out and signed	At any time post randomisation until end of Holter recording (18-24 hours post start of drug infusion).
Conversion of Atrial Fibrillation (AF) and Maintenance of Sinus Rhytm (SR)	Conversion of AF to SR with maintenance of SR maintained for at least 1 minute	Within 90 minutes from start of infusion

Secondary Outcomes

Measure	Description	Time Frame
Wide QRS Tachycardias	Number of patients with wide QRS tachycardias, determined as significant arrhythmias by an Adjudication Committee (AC). The AC analysed and classified the occurrence of significant arrhythmias (other than AF or AFl) and pauses based on the 12-lead Holter reports. All pauses (≥3 sec) and all wide QRS complex tachycardias (≥3 beats, QRS ≥120 ms, and ≥120 bpm).	From start of study drug infusion until discharge from hospital on study day 2.

Eligibility Module

Contacts/Locations Module

Overall Officials

Name	Affiliation	Role
AZD1305 Medical Science Director	AstraZeneca R&D, Mölndal, Sweden	Study Director
Aladár Rónaszéki	Péterfy HospitalDepartment of Cardiology1076 Budapest, Péterfi Sándor str. 8-20HUNGARY	Principal Investigator

Facility	Status	City	State	ZIP	Country	Contacts
Research Site		Brno	CZ		Czechia
Research Site

References Module

Citations

PubMed Identifier	Type	Citation	Retractions
21561900	Derived	Ronaszeki A, Alings M, Egstrup K, Gaciong Z, Hranai M, Kiraly C, Sereg M, Figatowski W, Bondarov P, Johansson S, Frison L, Edvardsson N, Berggren A. Pharmacological cardioversion of atrial fibrillation--a double-blind, randomized, placebo-controlled, multicentre, dose-escalation study of AZD1305 given intravenously. Europace. 2011 Aug;13(8):1148-56. doi: 10.1093/europace/eur120. Epub 2011 May 11.

IPD Sharing Statement Module

No data available

No data is available for this block.

Results Section

Participant Flow Module

Arm/Group Information

ID	Title	Description
FG000	AZD1305 Dose Group 1	AZD1305, intravenous (IV) single infusion given intravenously until successful conversion of Atrial Fibrillation to Sinus Rhythm occur or for a maximum of 30 minutes. Infusion rate 120 ml/h, dose rate 50 mg/h.
FG001	AZD1305 Dose Group 2

Baseline Characteristics Module

Outcome Measures Module

Adverse Events Module

More Info Module

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Submission Tracking

No data available

No data is available for this block.

Condition Browse Module

Intervention Browse Module

Masking Info

Type of Units Analyzed

Arm/Group Information

ID	Title	Description
BG000	AZD1305 Dose Group 1	AZD1305, intravenous (IV) single infusion given intravenously until successful conversion of Atrial Fibrillation to Sinus Rhythm occur or for a maximum of 30 minutes. Infusion rate 120 ml/h, dose rate 50 mg/h.
BG001	AZD1305 Dose Group 2	AZD1305, iv single infusion given intravenously until successful conversion of Atrial Fibrillation to Sinus Rhythm occur or for a maximum of 30 minutes. Infusion rate 120 ml/h, dose rate 101 mg/h.
BG002	AZD1305 Dose Group 3	AZD1305, iv single infusion given intravenously until successful conversion of Atrial Fibrillation to Sinus Rhythm occur or for a maximum of 30 minutes. Infusion rate 120 ml/h, dose rate 130 mg/h.
BG003	AZD1305 Dose Group 4	AZD1305, iv single infusion given intravenously until successful conversion of Atrial Fibrillation to Sinus Rhythm occur or for a maximum of 30 minutes. Infusion rate 120 ml/h, dose rate 180 mg/h.
BG004	Placebo	Sodium chloride, iv single infusion given intravenously until successful conversion of Atrial Fibrillation to Sinus Rhythm occur or for a maximum of 30 minutes. Infusion rate 120 ml/h.
BG005	Total	Total of all reporting groups

Baseline Measures

Title

Description

Population Description

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Denominator Units Selected

Denominators

Classes

Age Continuous

Mean

Standard Deviation

Years

Title

Denominators

Categories

Title	Measurements
	OG000461(449 to 474) OG001486(476 to 495) OG002490(480 to 499) OG003

Primary

Conversion of Atrial Fibrillation (AF) and Maintenance of Sinus Rhytm (SR)

Conversion of AF to SR with maintenance of SR maintained for at least 1 minute

Posted

Number

95% Confidence Interval

Percentage of patients converted to SR

Within 90 minutes from start of infusion

ID	Title	Description
OG000	AZD1305 Dose Group 1	AZD1305, intravenous (IV) single infusion given intravenously until successful conversion of Atrial Fibrillation to Sinus Rhythm occur or for a maximum of 30 minutes. Infusion rate 120 ml/h, dose rate 50 mg/h.
OG001	AZD1305 Dose Group 2	AZD1305, iv single infusion given intravenously until successful conversion of Atrial Fibrillation to Sinus Rhythm occur or for a maximum of 30 minutes. Infusion rate 120 ml/h, dose rate 101 mg/h.
OG002	AZD1305 Dose Group 3	AZD1305, iv single infusion given intravenously until successful conversion of Atrial Fibrillation to Sinus Rhythm occur or for a maximum of 30 minutes. Infusion rate 120 ml/h, dose rate 130 mg/h.
OG003	AZD1305 Dose Group 4

Secondary

Wide QRS Tachycardias

Number of patients with wide QRS tachycardias, determined as significant arrhythmias by an Adjudication Committee (AC). The AC analysed and classified the occurrence of significant arrhythmias (other than AF or AFl) and pauses based on the 12-lead Holter reports. All pauses (≥3 sec) and all wide QRS complex tachycardias (≥3 beats, QRS ≥120 ms, and ≥120 bpm).

Posted

Number

Participants

From start of study drug infusion until discharge from hospital on study day 2.

ID	Title	Description
OG000	AZD1305 Dose Group 1	AZD1305, intravenous (IV) single infusion given intravenously until successful conversion of Atrial Fibrillation to Sinus Rhythm occur or for a maximum of 30 minutes. Infusion rate 120 ml/h, dose rate 50 mg/h.
OG001	AZD1305 Dose Group 2	AZD1305, iv single infusion given intravenously until successful conversion of Atrial Fibrillation to Sinus Rhythm occur or for a maximum of 30 minutes. Infusion rate 120 ml/h, dose rate 101 mg/h.
OG002	AZD1305 Dose Group 3	AZD1305, iv single infusion given intravenously until successful conversion of Atrial Fibrillation to Sinus Rhythm occur or for a maximum of 30 minutes. Infusion rate 120 ml/h, dose rate 130 mg/h.

Secondary

Heart Rhythm. Number of Participants With Early Relapse Into AF.

Early relapse into AF within 5 minutes from obtaining the defined criterion for conversion to SR (i.e.1 minute in SR). Patients never converted are not included in the analysis.

Posted

Number

Participants

Within 5 minutes following investigational product (IP) induced conversion, or direct current (DC) cardioversion, of AF to SR

ID	Title	Description
OG000	AZD1305 Dose Group 1	AZD1305, intravenous (IV) single infusion given intravenously until successful conversion of Atrial Fibrillation to Sinus Rhythm occur or for a maximum of 30 minutes. Infusion rate 120 ml/h, dose rate 50 mg/h.
OG001	AZD1305 Dose Group 2	AZD1305, iv single infusion given intravenously until successful conversion of Atrial Fibrillation to Sinus Rhythm occur or for a maximum of 30 minutes. Infusion rate 120 ml/h, dose rate 101 mg/h.
OG002	AZD1305 Dose Group 3	AZD1305, iv single infusion given intravenously until successful conversion of Atrial Fibrillation to Sinus Rhythm occur or for a maximum of 30 minutes. Infusion rate 120 ml/h, dose rate 130 mg/h.
OG003

Secondary

Heart Rhythm. Number of Patients Remaining in SR up to 24 h Following Start of Study Drug Infusion

Posted

Number

Participants

During 24 hours following start of study drug infusion

ID	Title	Description
OG000	AZD1305 Dose Group 1	AZD1305, intravenous (IV) single infusion given intravenously until successful conversion of Atrial Fibrillation to Sinus Rhythm occur or for a maximum of 30 minutes. Infusion rate 120 ml/h, dose rate 50 mg/h.
OG001	AZD1305 Dose Group 2	AZD1305, iv single infusion given intravenously until successful conversion of Atrial Fibrillation to Sinus Rhythm occur or for a maximum of 30 minutes. Infusion rate 120 ml/h, dose rate 101 mg/h.
OG002	AZD1305 Dose Group 3	AZD1305, iv single infusion given intravenously until successful conversion of Atrial Fibrillation to Sinus Rhythm occur or for a maximum of 30 minutes. Infusion rate 120 ml/h, dose rate 130 mg/h.
OG003	AZD1305 Dose Group 4	AZD1305, iv single infusion given intravenously until successful conversion of Atrial Fibrillation to Sinus Rhythm occur or for a maximum of 30 minutes. Infusion rate 120 ml/h, dose rate 180 mg/h.

Secondary

Heart Rhythm. Number of Patients Remaining in SR up to 13 to 18 Days Following Study Drug Infusion.

Number of patients in SR at day 13-18

Posted

Number

Participants

During 13 to 18 days following study drug infusion

ID	Title	Description
OG000	AZD1305 Dose Group 1	AZD1305, intravenous (IV) single infusion given intravenously until successful conversion of Atrial Fibrillation to Sinus Rhythm occur or for a maximum of 30 minutes. Infusion rate 120 ml/h, dose rate 50 mg/h.
OG001	AZD1305 Dose Group 2	AZD1305, iv single infusion given intravenously until successful conversion of Atrial Fibrillation to Sinus Rhythm occur or for a maximum of 30 minutes. Infusion rate 120 ml/h, dose rate 101 mg/h.
OG002	AZD1305 Dose Group 3	AZD1305, iv single infusion given intravenously until successful conversion of Atrial Fibrillation to Sinus Rhythm occur or for a maximum of 30 minutes. Infusion rate 120 ml/h, dose rate 130 mg/h.
OG003	AZD1305 Dose Group 4	AZD1305, iv single infusion given intravenously until successful conversion of Atrial Fibrillation to Sinus Rhythm occur or for a maximum of 30 minutes. Infusion rate 120 ml/h, dose rate 180 mg/h.

Secondary

Study the Relationship Between Systemic Exposure and Response, With Special Regards to Conversion of AF to SR and the Effect on the QTcF Interval.

Not Posted

Since this study is no longer intended to be part of any marketing authorisation application, the analyses addressing this objective were not conducted.

Secondary

Maximal Observed Plasma Concentration of AZD1305

Plasma concentration of AZD1305

Posted

Median

Full Range

mol/L

Up to 24 hours following start of study drug infusion

ID	Title	Description
OG000	AZD1305 Dose Group 1	AZD1305, intravenous (IV) single infusion given intravenously until successful conversion of Atrial Fibrillation to Sinus Rhythm occur or for a maximum of 30 minutes. Infusion rate 120 ml/h, dose rate 50 mg/h.
OG001	AZD1305 Dose Group 2	AZD1305, iv single infusion given intravenously until successful conversion of Atrial Fibrillation to Sinus Rhythm occur or for a maximum of 30 minutes. Infusion rate 120 ml/h, dose rate 101 mg/h.
OG002	AZD1305 Dose Group 3	AZD1305, iv single infusion given intravenously until successful conversion of Atrial Fibrillation to Sinus Rhythm occur or for a maximum of 30 minutes. Infusion rate 120 ml/h, dose rate 130 mg/h.
OG003	AZD1305 Dose Group 4	AZD1305, iv single infusion given intravenously until successful conversion of Atrial Fibrillation to Sinus Rhythm occur or for a maximum of 30 minutes. Infusion rate 120 ml/h, dose rate 180 mg/h.

Secondary

Conversion From AF to SR Within 90 Minutes From Start of Infusion in the Subgroup of Patients With Duration of Current AF Episode 10 Hours to 7 Days

Posted

Number

Participants

Conversion from AF to SR within 90 minutes from start of infusion

ID	Title	Description
OG000	AZD1305 Dose Group 1	AZD1305, intravenous (IV) single infusion given intravenously until successful conversion of Atrial Fibrillation to Sinus Rhythm occur or for a maximum of 30 minutes. Infusion rate 120 ml/h, dose rate 50 mg/h.
OG001	AZD1305 Dose Group 2	AZD1305, iv single infusion given intravenously until successful conversion of Atrial Fibrillation to Sinus Rhythm occur or for a maximum of 30 minutes. Infusion rate 120 ml/h, dose rate 101 mg/h.
OG002	AZD1305 Dose Group 3	AZD1305, iv single infusion given intravenously until successful conversion of Atrial Fibrillation to Sinus Rhythm occur or for a maximum of 30 minutes. Infusion rate 120 ml/h, dose rate 130 mg/h.
OG003	AZD1305 Dose Group 4	AZD1305, iv single infusion given intravenously until successful conversion of Atrial Fibrillation to Sinus Rhythm occur or for a maximum of 30 minutes. Infusion rate 120 ml/h, dose rate 180 mg/h.

Secondary

Conversion From AF to SR Within 90 Minutes From Start of Infusion in the Subgroup of Patients With Duration of Current AF Episode 8 Days - 30 Days.

Subgroup analysis for patients with duration of current AF episode 8 days - 30 days. Number of patients converting from AF to SR.

Posted

Number

Participants

Conversion from AF to SR within 90 minutes from start of infusion

ID	Title	Description
OG000	AZD1305 Dose Group 1	AZD1305, intravenous (IV) single infusion given intravenously until successful conversion of Atrial Fibrillation to Sinus Rhythm occur or for a maximum of 30 minutes. Infusion rate 120 ml/h, dose rate 50 mg/h.
OG001	AZD1305 Dose Group 2	AZD1305, iv single infusion given intravenously until successful conversion of Atrial Fibrillation to Sinus Rhythm occur or for a maximum of 30 minutes. Infusion rate 120 ml/h, dose rate 101 mg/h.
OG002	AZD1305 Dose Group 3	AZD1305, iv single infusion given intravenously until successful conversion of Atrial Fibrillation to Sinus Rhythm occur or for a maximum of 30 minutes. Infusion rate 120 ml/h, dose rate 130 mg/h.
OG003	AZD1305 Dose Group 4

Secondary

Conversion From AF to SR Within 90 Minutes From Start of Infusion in the Subgroup of Patients With Duration of Current AF Episode 31 Days - 3 Months

Subgroup analysis for patients with duration of current AF episode 31 days - 3 months. Number of patients converting from AF to SR.

Posted

Number

Participants

Conversion from AF to SR within 90 minutes from start of infusion

ID	Title	Description
OG000	AZD1305 Dose Group 1	AZD1305, intravenous (IV) single infusion given intravenously until successful conversion of Atrial Fibrillation to Sinus Rhythm occur or for a maximum of 30 minutes. Infusion rate 120 ml/h, dose rate 50 mg/h.
OG001	AZD1305 Dose Group 2	AZD1305, iv single infusion given intravenously until successful conversion of Atrial Fibrillation to Sinus Rhythm occur or for a maximum of 30 minutes. Infusion rate 120 ml/h, dose rate 101 mg/h.
OG002	AZD1305 Dose Group 3	AZD1305, iv single infusion given intravenously until successful conversion of Atrial Fibrillation to Sinus Rhythm occur or for a maximum of 30 minutes. Infusion rate 120 ml/h, dose rate 130 mg/h.
OG003	AZD1305 Dose Group 4

Secondary

Percentage of Patients, Discharged Within 6 h (QTcF ≤500 ms) After Start of Infusion

Percentage, with 95% confidence interval, of patients with QTcF≤500 ms six hours following start of study drug infusion

Posted

Number

95% Confidence Interval

Percent of participants

Six hours following start of study drug infusion

ID	Title	Description
OG000	AZD1305 Dose Group 1	AZD1305, intravenous (IV) single infusion given intravenously until successful conversion of Atrial Fibrillation to Sinus Rhythm occur or for a maximum of 30 minutes. Infusion rate 120 ml/h, dose rate 50 mg/h.
OG001	AZD1305 Dose Group 2	AZD1305, iv single infusion given intravenously until successful conversion of Atrial Fibrillation to Sinus Rhythm occur or for a maximum of 30 minutes. Infusion rate 120 ml/h, dose rate 101 mg/h.
OG002	AZD1305 Dose Group 3	AZD1305, iv single infusion given intravenously until successful conversion of Atrial Fibrillation to Sinus Rhythm occur or for a maximum of 30 minutes. Infusion rate 120 ml/h, dose rate 130 mg/h.
OG003	AZD1305 Dose Group 4

Arm/Groups

ID	Title	Description	Serious Events (Affected)	Other Events (Affected)	Other Events (At Risk)
EG000	AZD1305 Dose Group 1	AZD1305, intravenous (IV) single infusion given intravenously until successful conversion of Atrial Fibrillation to Sinus Rhythm occur or for a maximum of 30 minutes. Infusion rate 120 ml/h, dose rate 50 mg/h.	1	5	26
EG001	AZD1305 Dose Group 2	AZD1305, iv single infusion given intravenously until successful conversion of Atrial Fibrillation to Sinus Rhythm occur or for a maximum of 30 minutes. Infusion rate 120 ml/h, dose rate 101 mg/h.	3	9	45
EG002	AZD1305 Dose Group 3	AZD1305, iv single infusion given intravenously until successful conversion of Atrial Fibrillation to Sinus Rhythm occur or for a maximum of 30 minutes. Infusion rate 120 ml/h, dose rate 130 mg/h.	3	8	45
EG003	AZD1305 Dose Group 4	AZD1305, iv single infusion given intravenously until successful conversion of Atrial Fibrillation to Sinus Rhythm occur or for a maximum of 30 minutes. Infusion rate 120 ml/h, dose rate 180 mg/h.	1	3	12
EG004	Placebo	Sodium chloride, iv single infusion given intravenously until successful conversion of Atrial Fibrillation to Sinus Rhythm occur or for a maximum of 30 minutes. Infusion rate 120 ml/h.	2	5	43

Serious Adverse Events

Term	Organ System	Source Vocabulary	Assessment Type	Statistical Information
Atrial fibrillation	Cardiac disorders	MedDRA 10.0	Systematic Assessment	EG0001 affected26 at risk EG0011 affected45 at risk EG0020 affected45 at risk EG0030 affected12 at risk EG0040 affected43 at risk
Sinus bradycardia	Cardiac disorders	MedDRA 10.0	Systematic Assessment	EG0001 affected26 at risk EG0010 affected45 at risk EG0020 affected45 at risk EG003
Cerebrovascular accident	Nervous system disorders	MedDRA 10.0	Systematic Assessment	EG0000 affected26 at risk EG0011 affected45 at risk EG0020 affected45 at risk EG003
Multiple drug overdose	Injury, poisoning and procedural complications	MedDRA 10.0	Systematic Assessment	EG0000 affected26 at risk EG0011 affected45 at risk EG0020 affected45 at risk EG003
Torsade de pointes	Cardiac disorders	MedDRA 10.0	Systematic Assessment	EG0000 affected26 at risk EG0010 affected45 at risk EG0021 affected45 at risk EG003
Transient ischaemic attack	Nervous system disorders	MedDRA 10.0	Systematic Assessment	EG0000 affected26 at risk EG0010 affected45 at risk EG0021 affected45 at risk EG003
Cardiac asthma	Cardiac disorders	MedDRA 10.0	Systematic Assessment	EG0000 affected26 at risk EG0010 affected45 at risk EG0021 affected45 at risk EG003
Urinary tract infection	Infections and infestations	MedDRA 10.0	Systematic Assessment	EG0000 affected26 at risk EG0010 affected45 at risk EG0021 affected45 at risk EG003
Ventricular tachycardia	Cardiac disorders	MedDRA 10.0	Systematic Assessment	EG0000 affected26 at risk EG0010 affected45 at risk EG0020 affected45 at risk EG003
Presyncope	Nervous system disorders	MedDRA 10.0	Systematic Assessment	EG0000 affected26 at risk EG0010 affected45 at risk EG0020 affected45 at risk EG003
Chronic obstructive pulmonary disease	Respiratory, thoracic and mediastinal disorders	MedDRA 10.0	Systematic Assessment	EG0000 affected26 at risk EG0010 affected45 at risk EG0020 affected45 at risk EG003
Abdominal wall haematoma	Gastrointestinal disorders	MedDRA 10.0	Systematic Assessment	EG0000 affected26 at risk EG0010 affected45 at risk EG0020 affected45 at risk EG003

Other Adverse Events

Term	Organ System	Source Vocabulary	Assessment Type	Statistical Information
Bradycardia	Cardiac disorders	MedDRA 10.0	Systematic Assessment	EG0000 affected26 at risk EG0010 affected45 at risk EG0020 affected45 at risk EG0031 affected12 at risk EG0040 affected43 at risk
Ventricular tachycardia	Cardiac disorders	MedDRA 10.0	Systematic Assessment	EG0001 affected26 at risk EG0010 affected45 at risk EG0020 affected45 at risk EG003
Dizziness	Nervous system disorders	MedDRA 10.0	Systematic Assessment	EG0001 affected26 at risk EG0010 affected45 at risk EG0021 affected45 at risk EG003
Atrial fibrillation	Cardiac disorders	MedDRA 10.0	Systematic Assessment	EG0003 affected26 at risk EG0016 affected45 at risk EG0025 affected45 at risk EG003
Angina pectoris	Cardiac disorders	MedDRA 10.0	Systematic Assessment	EG0002 affected26 at risk EG0010 affected45 at risk EG0020 affected45 at risk EG003
Presyncope	Nervous system disorders	MedDRA 10.0	Systematic Assessment	EG0000 affected26 at risk EG0010 affected45 at risk EG0020 affected45 at risk EG003
Tension headache	Nervous system disorders	MedDRA 10.0	Systematic Assessment	EG0000 affected26 at risk EG0010 affected45 at risk EG0020 affected45 at risk EG003
Gastritis fungal	Infections and infestations	MedDRA 10.0	Systematic Assessment	EG0000 affected26 at risk EG0010 affected45 at risk EG0020 affected45 at risk EG003
Hypertension	Vascular disorders	MedDRA 10.0	Systematic Assessment	EG0000 affected26 at risk EG0013 affected45 at risk EG0022 affected45 at risk EG003
Sensation of heaviness	Musculoskeletal and connective tissue disorders	MedDRA 10.0	Systematic Assessment	EG0000 affected26 at risk EG0010 affected45 at risk EG0020 affected45 at risk EG003

ID	Term
D001281	Atrial Fibrillation

ID	Term
C550721	tert-butyl (2-(7-(2-(4-cyano-2-fluorophenoxy)ethyl)-9-oxa-3,7-diazabicyclo(3.3.1)non3-yl)ethyl)carbamate

OG004440(430 to 450)

AZD1305, iv single infusion given intravenously until successful conversion of Atrial Fibrillation to Sinus Rhythm occur or for a maximum of 30 minutes. Infusion rate 120 ml/h, dose rate 180 mg/h.

EG0040 affected43 at risk

EG0041 affected43 at risk

EG0040 affected43 at risk

EG0041 affected43 at risk

EG0044 affected43 at risk

EG0040 affected43 at risk

ID	Term
D001145	Arrhythmias, Cardiac
D006331	Heart Diseases
D002318	Cardiovascular Diseases
D010335	Pathologic Processes
D013568	Pathological Conditions, Signs and Symptoms